1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Abbott Inks Partnership to Connect Its Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices

10 Aug 2024
Admin
News Article

Abbott Inks Partnership to Connect Its Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices

Overview

Abbott announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

Post Integration

The integration of Abbott's CGM sensor with Medtronic's AID algorithms will enable automatic adjustments of insulin to keep glucose in range.
The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic.

AID Systems Benefits

AID systems improve health outcomes while reducing the burden of constant decision-making for people with diabetes who use intensive insulin as part of their overall therapy.
AID systems can benefit people with both type 1 and type 2 diabetes who require multiple daily injections of rapid-acting insulin, currently estimated at more than 11 million people globally.

Financial terms of the partnership and timing for commercial availability were not disclosed.

From Abbott's Diabetes Care Business

"This partnership pairs two global leaders in glucose sensing technology and insulin delivery," said Jared Watkin, executive vice president of Abbott's diabetes care business.
"Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic's insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living."

From the President: Medtronic Diabetes

"Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world," said Que Dallara, executive vice president and president, Medtronic Diabetes.
"We're committed to simplifying diabetes management and making the transition to automated technology much more seamless for those who wish to achieve more with their diabetes care."

The Current Collaboration

This collaboration with Medtronic is the latest in a series of Abbott partnerships aimed at improving and streamlining diabetes care, giving people more choices to confidently administer their insulin.
Abbott's Libre single-analyte CGM technology is currently available and integrated with AID offerings from other insulin delivery companies.

Abbott's Libre Portfolio

Abbott's Libre portfolio is the world's leading continuous glucose monitoring technology, now used by more than 6 million people in more than 60 countries.
Clinical and real-world data from the millions of people that use Libre systems show that the technology helps people improve their glucose control, lower their HbA1c, decrease diabetes-related hospital admissions, and improve their quality of life.
The systems have partial or full reimbursement in more than 40 countries.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life.
Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines.